No­vo Nordisk re­mains un­der UK scruti­ny as MHRA con­ducts its own re­view in 'in­cred­i­bly rare' case

The UK’s Med­i­cines and Health­care prod­ucts Reg­u­la­to­ry Agency is now re­view­ing No­vo Nordisk’s mar­ket­ing vi­o­la­tion that re­sult­ed in its loss of UK trade group mem­ber­ship last week. No­vo Nordisk was sus­pend­ed on Thurs­day from the As­so­ci­a­tion of the British Phar­ma­ceu­ti­cal In­dus­try (ABPI) for two years af­ter an in­ves­ti­ga­tion by its reg­u­la­to­ry arm found the phar­ma broke its con­duct rules.

MHRA said on Tues­day that its re­view of the Pre­scrip­tion Med­i­cines Code of Prac­tice Au­thor­i­ty (PM­C­PA) in­ves­ti­ga­tion is stan­dard prac­tice. An MHRA spokesper­son em­pha­sized in an email to End­points News that the sit­u­a­tion with No­vo Nordisk is “in­cred­i­bly rare” while al­so not­ing ABPI took “swift and pro­por­tion­ate ac­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER